yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q26998884-5C9A9FE2-8BDF-401A-BF0E-42F2FA6B4E62
Q26998884-5C9A9FE2-8BDF-401A-BF0E-42F2FA6B4E62
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26998884-5C9A9FE2-8BDF-401A-BF0E-42F2FA6B4E62
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
P2860
Q26998884-5C9A9FE2-8BDF-401A-BF0E-42F2FA6B4E62
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26998884-5C9A9FE2-8BDF-401A-BF0E-42F2FA6B4E62
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f9067250520fe4f0ee00d72cead89dc975965e7c
P2860
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.